New Economy Portfolio..bought a stock that is trading like it wants to move much higher soon. For folks that missed my $SYN alert at $2.20 last week (it’s $3.00 now) this stock is near the same price that stock was at $2.20 range before heading higher. Lots of catalysts here moving forward. A licensing deal by YE, Updated Ph 1 data at HepDart 2015 2nd week of December, also expecting word from FDA on IND filing for HBV, Ph 2 studies to commence in 2016. This company which has a pro drug similar to Gilead’s Tenofovir has been discussed as being better tolerated that the gold standard. Company has a market cap under $60m and bought CMX-157 from Chimerix (2B marketcap). 52wk low is $1.05 & 52wk high is $6.28.
Alert..bought $CTRV at $2.13 in the New Economy Portfolio with a 15% (Full) position. This stock has excellent prospects moving forward.
ContraVirPharma: #HepatitisB is the next frontier! $CTRV CEO in @Bloomberg ‘Hepatitis Quest Moves From C to B Under Ex-Gilead Leaders’ http://t.co/sgwuyOntBn
@ContraVirPharma: We plan to file an IND for CMX157 to treat #HBV before year-end 2015, Ph 2 Study to commence in 2016 http://t.co/bDjUpIv3Mr $CTRV
$CTRV Public Offering Results in $15 Million of Gross Proceeds - @DavidBautz >> https://t.co/qSPOEYPx9X (Did the offering at $3/share. Price now at $2.15)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.